nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—CSF3—liver cancer	0.0532	0.084	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—NDRG1—liver cancer	0.0368	0.0581	CbGpPWpGaD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CCR4—liver cancer	0.0342	0.054	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—CCR4—liver cancer	0.0274	0.0432	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—HNF4A—liver cancer	0.0255	0.0403	CbGpPWpGaD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—CSF2—liver cancer	0.0228	0.036	CbGpPWpGaD
Plerixafor—Haematoma—Sorafenib—liver cancer	0.0216	0.0588	CcSEcCtD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—F2—liver cancer	0.0214	0.0338	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—IGF2—liver cancer	0.0195	0.0308	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—HMOX1—liver cancer	0.0166	0.0262	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—VEGFA—liver cancer	0.0149	0.0236	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—KDR—liver cancer	0.0148	0.0234	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—MAPK14—liver cancer	0.0147	0.0233	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—MMP9—liver cancer	0.0136	0.0215	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—TERT—liver cancer	0.0136	0.0215	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCR4—liver cancer	0.0129	0.0203	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—CCR4—liver cancer	0.0109	0.0172	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.0101	0.0159	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—SERPINE1—liver cancer	0.00997	0.0158	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—AKT1—liver cancer	0.00951	0.015	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CG—liver cancer	0.00946	0.0149	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APCS—liver cancer	0.00943	0.0149	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.00863	0.0136	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—PSMA4—liver cancer	0.00863	0.0136	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—PSMD10—liver cancer	0.00863	0.0136	CbGpPWpGaD
Plerixafor—Abdominal discomfort—Sorafenib—liver cancer	0.00816	0.0222	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—JUN—liver cancer	0.00785	0.0124	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—TGFB1—liver cancer	0.0075	0.0119	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CB—liver cancer	0.00725	0.0114	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MTOR—liver cancer	0.00725	0.0114	CbGpPWpGaD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL6—liver cancer	0.00708	0.0112	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—VEGFA—liver cancer	0.00686	0.0108	CbGpPWpGaD
Plerixafor—Haemoglobin—Sorafenib—liver cancer	0.00685	0.0187	CcSEcCtD
Plerixafor—Haemorrhage—Sorafenib—liver cancer	0.00682	0.0186	CcSEcCtD
Plerixafor—Connective tissue disorder—Sorafenib—liver cancer	0.0067	0.0182	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CCR4—liver cancer	0.00657	0.0104	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MMP9—liver cancer	0.0063	0.00995	CbGpPWpGaD
Plerixafor—Immune system disorder—Sorafenib—liver cancer	0.00616	0.0168	CcSEcCtD
Plerixafor—Mental disorder—Sorafenib—liver cancer	0.00597	0.0163	CcSEcCtD
Plerixafor—Erythema—Sorafenib—liver cancer	0.00593	0.0162	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—STAT3—liver cancer	0.0056	0.00885	CbGpPWpGaD
Plerixafor—Syncope—Sorafenib—liver cancer	0.00532	0.0145	CcSEcCtD
Plerixafor—Loss of consciousness—Sorafenib—liver cancer	0.00521	0.0142	CcSEcCtD
Plerixafor—Inflammation—Epirubicin—liver cancer	0.00517	0.0141	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—F2—liver cancer	0.00514	0.00813	CbGpPWpGaD
Plerixafor—Musculoskeletal pain—Epirubicin—liver cancer	0.00508	0.0138	CcSEcCtD
Plerixafor—Arthralgia—Sorafenib—liver cancer	0.00505	0.0138	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00502	0.0137	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CHN2—liver cancer	0.00501	0.00791	CbGpPWpGaD
Plerixafor—Injection site reaction—Epirubicin—liver cancer	0.00499	0.0136	CcSEcCtD
Plerixafor—Dry mouth—Sorafenib—liver cancer	0.00494	0.0135	CcSEcCtD
Plerixafor—Anaphylactic shock—Sorafenib—liver cancer	0.00484	0.0132	CcSEcCtD
Plerixafor—Inflammation—Doxorubicin—liver cancer	0.00478	0.013	CcSEcCtD
Plerixafor—Shock—Sorafenib—liver cancer	0.00476	0.013	CcSEcCtD
Plerixafor—Nervous system disorder—Sorafenib—liver cancer	0.00475	0.0129	CcSEcCtD
Plerixafor—Skin disorder—Sorafenib—liver cancer	0.0047	0.0128	CcSEcCtD
Plerixafor—Musculoskeletal pain—Doxorubicin—liver cancer	0.0047	0.0128	CcSEcCtD
Plerixafor—Injection site reaction—Doxorubicin—liver cancer	0.00461	0.0126	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—IFT88—liver cancer	0.00458	0.00723	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CA—liver cancer	0.00442	0.00698	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00441	0.012	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—AKT1—liver cancer	0.00438	0.00691	CbGpPWpGaD
Plerixafor—Dyspnoea—Sorafenib—liver cancer	0.00432	0.0118	CcSEcCtD
Plerixafor—Dyspepsia—Sorafenib—liver cancer	0.00426	0.0116	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Sorafenib—liver cancer	0.00418	0.0114	CcSEcCtD
Plerixafor—Fatigue—Sorafenib—liver cancer	0.00417	0.0114	CcSEcCtD
Plerixafor—Pain—Sorafenib—liver cancer	0.00414	0.0113	CcSEcCtD
Plerixafor—Constipation—Sorafenib—liver cancer	0.00414	0.0113	CcSEcCtD
Plerixafor—Gastrointestinal pain—Sorafenib—liver cancer	0.00396	0.0108	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—TRIO—liver cancer	0.00387	0.00612	CbGpPWpGaD
Plerixafor—Urticaria—Sorafenib—liver cancer	0.00385	0.0105	CcSEcCtD
Plerixafor—Abdominal pain—Sorafenib—liver cancer	0.00383	0.0104	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CCR4—liver cancer	0.00371	0.00587	CbGpPWpGaD
Plerixafor—CXCR4—Disease—LTF—liver cancer	0.00368	0.00582	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—AKT1—liver cancer	0.00361	0.0057	CbGpPWpGaD
Plerixafor—Hypersensitivity—Sorafenib—liver cancer	0.00357	0.00972	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—TRIO—liver cancer	0.00352	0.00556	CbGpPWpGaD
Plerixafor—Asthenia—Sorafenib—liver cancer	0.00347	0.00947	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.00345	0.00545	CbGpPWpGaD
Plerixafor—Pruritus—Sorafenib—liver cancer	0.00343	0.00933	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CCR4—liver cancer	0.00337	0.00533	CbGpPWpGaD
Plerixafor—Orthostatic hypotension—Epirubicin—liver cancer	0.00333	0.00906	CcSEcCtD
Plerixafor—Diarrhoea—Sorafenib—liver cancer	0.00331	0.00903	CcSEcCtD
Plerixafor—Dizziness—Sorafenib—liver cancer	0.0032	0.00872	CcSEcCtD
Plerixafor—Abdominal distension—Epirubicin—liver cancer	0.00317	0.00863	CcSEcCtD
Plerixafor—Vomiting—Sorafenib—liver cancer	0.00308	0.00839	CcSEcCtD
Plerixafor—Orthostatic hypotension—Doxorubicin—liver cancer	0.00308	0.00838	CcSEcCtD
Plerixafor—Rash—Sorafenib—liver cancer	0.00305	0.00832	CcSEcCtD
Plerixafor—Dermatitis—Sorafenib—liver cancer	0.00305	0.00831	CcSEcCtD
Plerixafor—Headache—Sorafenib—liver cancer	0.00303	0.00826	CcSEcCtD
Plerixafor—Abdominal distension—Doxorubicin—liver cancer	0.00293	0.00799	CcSEcCtD
Plerixafor—Nausea—Sorafenib—liver cancer	0.00288	0.00784	CcSEcCtD
Plerixafor—CXCR4—Disease—ALDOB—liver cancer	0.00285	0.0045	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SHC3—liver cancer	0.00281	0.00443	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—F2—liver cancer	0.00263	0.00415	CbGpPWpGaD
Plerixafor—Haemoglobin—Epirubicin—liver cancer	0.00253	0.0069	CcSEcCtD
Plerixafor—Haemorrhage—Epirubicin—liver cancer	0.00252	0.00686	CcSEcCtD
Plerixafor—Connective tissue disorder—Epirubicin—liver cancer	0.00248	0.00674	CcSEcCtD
Plerixafor—Haemoglobin—Doxorubicin—liver cancer	0.00234	0.00638	CcSEcCtD
Plerixafor—Haemorrhage—Doxorubicin—liver cancer	0.00233	0.00635	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—liver cancer	0.00229	0.00624	CcSEcCtD
Plerixafor—Immune system disorder—Epirubicin—liver cancer	0.00228	0.0062	CcSEcCtD
Plerixafor—CXCR4—Disease—ADAM17—liver cancer	0.00225	0.00355	CbGpPWpGaD
Plerixafor—Mental disorder—Epirubicin—liver cancer	0.00221	0.00601	CcSEcCtD
Plerixafor—Erythema—Epirubicin—liver cancer	0.00219	0.00597	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FST—liver cancer	0.00218	0.00344	CbGpPWpGaD
Plerixafor—Flatulence—Epirubicin—liver cancer	0.00216	0.00589	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PRKCE—liver cancer	0.00214	0.00338	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PSMD10—liver cancer	0.00211	0.00334	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PSMA4—liver cancer	0.00211	0.00334	CbGpPWpGaD
Plerixafor—Immune system disorder—Doxorubicin—liver cancer	0.00211	0.00574	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TRIO—liver cancer	0.00208	0.00328	CbGpPWpGaD
Plerixafor—CXCR4—Disease—GOT2—liver cancer	0.00206	0.00325	CbGpPWpGaD
Plerixafor—Mental disorder—Doxorubicin—liver cancer	0.00204	0.00556	CcSEcCtD
Plerixafor—Ill-defined disorder—Epirubicin—liver cancer	0.00203	0.00554	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—liver cancer	0.00203	0.00553	CcSEcCtD
Plerixafor—Flatulence—Doxorubicin—liver cancer	0.002	0.00545	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CCR4—liver cancer	0.00199	0.00315	CbGpPWpGaD
Plerixafor—Malaise—Epirubicin—liver cancer	0.00198	0.00539	CcSEcCtD
Plerixafor—Syncope—Epirubicin—liver cancer	0.00197	0.00536	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PRKCE—liver cancer	0.00194	0.00307	CbGpPWpGaD
Plerixafor—Loss of consciousness—Epirubicin—liver cancer	0.00193	0.00525	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CSF2—liver cancer	0.00189	0.00299	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Doxorubicin—liver cancer	0.00188	0.00513	CcSEcCtD
Plerixafor—Arthralgia—Epirubicin—liver cancer	0.00187	0.00509	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00185	0.00505	CcSEcCtD
Plerixafor—Discomfort—Epirubicin—liver cancer	0.00184	0.00502	CcSEcCtD
Plerixafor—Malaise—Doxorubicin—liver cancer	0.00183	0.00498	CcSEcCtD
Plerixafor—Dry mouth—Epirubicin—liver cancer	0.00183	0.00497	CcSEcCtD
Plerixafor—Syncope—Doxorubicin—liver cancer	0.00182	0.00496	CcSEcCtD
Plerixafor—Anaphylactic shock—Epirubicin—liver cancer	0.00179	0.00488	CcSEcCtD
Plerixafor—Loss of consciousness—Doxorubicin—liver cancer	0.00178	0.00486	CcSEcCtD
Plerixafor—CXCR4—Disease—GOT1—liver cancer	0.00178	0.00281	CbGpPWpGaD
Plerixafor—Shock—Epirubicin—liver cancer	0.00176	0.0048	CcSEcCtD
Plerixafor—Nervous system disorder—Epirubicin—liver cancer	0.00175	0.00478	CcSEcCtD
Plerixafor—Skin disorder—Epirubicin—liver cancer	0.00174	0.00474	CcSEcCtD
Plerixafor—Hyperhidrosis—Epirubicin—liver cancer	0.00173	0.00471	CcSEcCtD
Plerixafor—Arthralgia—Doxorubicin—liver cancer	0.00173	0.00471	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CSF2—liver cancer	0.00172	0.00271	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00172	0.00467	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—liver cancer	0.00171	0.00465	CcSEcCtD
Plerixafor—Dry mouth—Doxorubicin—liver cancer	0.00169	0.0046	CcSEcCtD
Plerixafor—Anaphylactic shock—Doxorubicin—liver cancer	0.00166	0.00451	CcSEcCtD
Plerixafor—CXCR4—Disease—PRKCE—liver cancer	0.00164	0.00259	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00163	0.00444	CcSEcCtD
Plerixafor—Shock—Doxorubicin—liver cancer	0.00163	0.00444	CcSEcCtD
Plerixafor—Nervous system disorder—Doxorubicin—liver cancer	0.00162	0.00442	CcSEcCtD
Plerixafor—Insomnia—Epirubicin—liver cancer	0.00162	0.00441	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—liver cancer	0.00161	0.00438	CcSEcCtD
Plerixafor—Paraesthesia—Epirubicin—liver cancer	0.00161	0.00438	CcSEcCtD
Plerixafor—Hyperhidrosis—Doxorubicin—liver cancer	0.0016	0.00436	CcSEcCtD
Plerixafor—Dyspnoea—Epirubicin—liver cancer	0.0016	0.00435	CcSEcCtD
Plerixafor—Dyspepsia—Epirubicin—liver cancer	0.00158	0.00429	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ADAM17—liver cancer	0.00158	0.00249	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Epirubicin—liver cancer	0.00154	0.00421	CcSEcCtD
Plerixafor—Fatigue—Epirubicin—liver cancer	0.00154	0.0042	CcSEcCtD
Plerixafor—Constipation—Epirubicin—liver cancer	0.00153	0.00417	CcSEcCtD
Plerixafor—Pain—Epirubicin—liver cancer	0.00153	0.00417	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00151	0.00411	CcSEcCtD
Plerixafor—Insomnia—Doxorubicin—liver cancer	0.0015	0.00408	CcSEcCtD
Plerixafor—Paraesthesia—Doxorubicin—liver cancer	0.00149	0.00405	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—F2—liver cancer	0.00148	0.00235	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PSMA4—liver cancer	0.00148	0.00234	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PSMD10—liver cancer	0.00148	0.00234	CbGpPWpGaD
Plerixafor—Dyspnoea—Doxorubicin—liver cancer	0.00148	0.00402	CcSEcCtD
Plerixafor—Feeling abnormal—Epirubicin—liver cancer	0.00147	0.00402	CcSEcCtD
Plerixafor—Gastrointestinal pain—Epirubicin—liver cancer	0.00146	0.00399	CcSEcCtD
Plerixafor—Dyspepsia—Doxorubicin—liver cancer	0.00146	0.00397	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00143	0.00389	CcSEcCtD
Plerixafor—CXCR4—Disease—H2AFX—liver cancer	0.00143	0.00226	CbGpPWpGaD
Plerixafor—Fatigue—Doxorubicin—liver cancer	0.00143	0.00389	CcSEcCtD
Plerixafor—Urticaria—Epirubicin—liver cancer	0.00142	0.00387	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CG—liver cancer	0.00142	0.00224	CbGpPWpGaD
Plerixafor—Constipation—Doxorubicin—liver cancer	0.00142	0.00386	CcSEcCtD
Plerixafor—Pain—Doxorubicin—liver cancer	0.00142	0.00386	CcSEcCtD
Plerixafor—Abdominal pain—Epirubicin—liver cancer	0.00141	0.00385	CcSEcCtD
Plerixafor—Feeling abnormal—Doxorubicin—liver cancer	0.00136	0.00372	CcSEcCtD
Plerixafor—Gastrointestinal pain—Doxorubicin—liver cancer	0.00135	0.00369	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—F2—liver cancer	0.00135	0.00213	CbGpPWpGaD
Plerixafor—Hypersensitivity—Epirubicin—liver cancer	0.00132	0.00359	CcSEcCtD
Plerixafor—Urticaria—Doxorubicin—liver cancer	0.00132	0.00358	CcSEcCtD
Plerixafor—Abdominal pain—Doxorubicin—liver cancer	0.00131	0.00357	CcSEcCtD
Plerixafor—CXCR4—Disease—MTHFR—liver cancer	0.0013	0.00205	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TERT—liver cancer	0.00129	0.00204	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CG—liver cancer	0.00129	0.00204	CbGpPWpGaD
Plerixafor—Asthenia—Epirubicin—liver cancer	0.00128	0.0035	CcSEcCtD
Plerixafor—Pruritus—Epirubicin—liver cancer	0.00127	0.00345	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CD—liver cancer	0.00125	0.00197	CbGpPWpGaD
Plerixafor—Diarrhoea—Epirubicin—liver cancer	0.00122	0.00334	CcSEcCtD
Plerixafor—Hypersensitivity—Doxorubicin—liver cancer	0.00122	0.00332	CcSEcCtD
Plerixafor—Asthenia—Doxorubicin—liver cancer	0.00119	0.00324	CcSEcCtD
Plerixafor—Dizziness—Epirubicin—liver cancer	0.00118	0.00322	CcSEcCtD
Plerixafor—Pruritus—Doxorubicin—liver cancer	0.00117	0.00319	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PRKCE—liver cancer	0.00115	0.00181	CbGpPWpGaD
Plerixafor—Vomiting—Epirubicin—liver cancer	0.00114	0.0031	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CD—liver cancer	0.00113	0.00179	CbGpPWpGaD
Plerixafor—Diarrhoea—Doxorubicin—liver cancer	0.00113	0.00309	CcSEcCtD
Plerixafor—Rash—Epirubicin—liver cancer	0.00113	0.00307	CcSEcCtD
Plerixafor—Dermatitis—Epirubicin—liver cancer	0.00113	0.00307	CcSEcCtD
Plerixafor—Headache—Epirubicin—liver cancer	0.00112	0.00305	CcSEcCtD
Plerixafor—Dizziness—Doxorubicin—liver cancer	0.00109	0.00298	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CB—liver cancer	0.00109	0.00172	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APC—liver cancer	0.00109	0.00172	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF2—liver cancer	0.00109	0.00172	CbGpPWpGaD
Plerixafor—Nausea—Epirubicin—liver cancer	0.00106	0.0029	CcSEcCtD
Plerixafor—Vomiting—Doxorubicin—liver cancer	0.00105	0.00287	CcSEcCtD
Plerixafor—Rash—Doxorubicin—liver cancer	0.00104	0.00284	CcSEcCtD
Plerixafor—Dermatitis—Doxorubicin—liver cancer	0.00104	0.00284	CcSEcCtD
Plerixafor—Headache—Doxorubicin—liver cancer	0.00104	0.00283	CcSEcCtD
Plerixafor—CXCR4—Disease—BRAF—liver cancer	0.00102	0.00162	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CSF2—liver cancer	0.00101	0.0016	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—RAF1—liver cancer	0.00101	0.0016	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—H2AFX—liver cancer	0.001	0.00158	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—IL2—liver cancer	0.001	0.00158	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CB—liver cancer	0.000989	0.00156	CbGpPWpGaD
Plerixafor—Nausea—Doxorubicin—liver cancer	0.000984	0.00268	CcSEcCtD
Plerixafor—CXCR4—Disease—PIK3CD—liver cancer	0.000957	0.00151	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SERPINE1—liver cancer	0.000946	0.0015	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL2—liver cancer	0.000908	0.00143	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TERT—liver cancer	0.000905	0.00143	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RAF1—liver cancer	0.000854	0.00135	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CB—liver cancer	0.000834	0.00132	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MTOR—liver cancer	0.000834	0.00132	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KDR—liver cancer	0.000827	0.00131	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK14—liver cancer	0.000822	0.0013	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ESR1—liver cancer	0.000806	0.00127	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—F2—liver cancer	0.000796	0.00126	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1B—liver cancer	0.000783	0.00124	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CG—liver cancer	0.000762	0.0012	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APC—liver cancer	0.000762	0.0012	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CTNNB1—liver cancer	0.000739	0.00117	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1A—liver cancer	0.000722	0.00114	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BRAF—liver cancer	0.000716	0.00113	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CD—liver cancer	0.00067	0.00106	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CA—liver cancer	0.000664	0.00105	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SERPINE1—liver cancer	0.000663	0.00105	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—liver cancer	0.000656	0.00104	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT3—liver cancer	0.000645	0.00102	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CA—liver cancer	0.000603	0.000952	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MYC—liver cancer	0.000599	0.000946	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RAF1—liver cancer	0.000598	0.000945	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TGFB1—liver cancer	0.000597	0.000944	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MTOR—liver cancer	0.000584	0.000923	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CB—liver cancer	0.000584	0.000923	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—liver cancer	0.000558	0.000881	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—liver cancer	0.000553	0.000874	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1B—liver cancer	0.000548	0.000866	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT1—liver cancer	0.000542	0.000857	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP3—liver cancer	0.000537	0.000849	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2—liver cancer	0.000536	0.000847	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6—liver cancer	0.000534	0.000843	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—liver cancer	0.000523	0.000826	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—JUN—liver cancer	0.000522	0.000824	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CTNNB1—liver cancer	0.000518	0.000818	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CA—liver cancer	0.000508	0.000803	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP9—liver cancer	0.000508	0.000802	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1A—liver cancer	0.000506	0.000799	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK8—liver cancer	0.000494	0.00078	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKT1—liver cancer	0.000492	0.000778	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—liver cancer	0.00047	0.000743	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—liver cancer	0.000456	0.00072	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STAT3—liver cancer	0.000451	0.000713	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6—liver cancer	0.00045	0.000711	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYC—liver cancer	0.000419	0.000663	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TGFB1—liver cancer	0.000418	0.000661	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT1—liver cancer	0.000415	0.000656	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—liver cancer	0.000388	0.000612	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CA—liver cancer	0.000356	0.000562	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—liver cancer	0.000344	0.000544	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—liver cancer	0.000329	0.00052	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6—liver cancer	0.000315	0.000498	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT1—liver cancer	0.000291	0.000459	CbGpPWpGaD
